Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  FUJIFILM Holdings Corporation    4901   JP3814000000

FUJIFILM HOLDINGS CORPORATION

(4901)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

FUJIFILM : Cellular Dynamics and Lonza Agree to Expand the Availability and Use of Induced Pluripotent Stem Cell Technology

11/13/2020 | 09:18am EST

Madison - FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC) technologies, and Lonza Walkersville, Inc. (Lonza, a leading global GMP iPSC manufacturer), have entered into a worldwide agreement.

The agreement enables drug developers to leverage both companies' expertise and technologies for the generation of iPSCs through licensing agreements.

Under the agreement, FUJIFILM Cellular Dynamics grants Lonza a non-exclusive right to use their patents related to iPSC generation, including episomal vectors and reprogramming factors, for the clinical manufacture and differentiation of iPSC lines for cell therapies. Furthermore, Lonza grants FUJIFILM Cellular Dynamics expanded use of its non-exclusive license to its innovative Nucleofector technology, to enable efficient transfection of cells, stem cell and cell lines.

Cell therapies have emerged as a promising treatment modality with the ability to augment, repair, or replace human biology, including organs, tissues and cells. Given their incredible capacity to self-renew and the ability to become many different cell types, iPSCs are a critical material used in the development and manufacture of cell therapies

About Lonza

At Lonza, we combine technological innovation with world class manufacturing and process excellence. Together, these enable our customers to deliver their discoveries in the healthcare, preservation, and protection sectors. We are a preferred global partner to the pharmaceutical, biotech and specialty ingredients markets. We work to prevent illness and promote a healthier world by enabling our customers to deliver innovative medicines that help treat or even cure a wide range of diseases. We also offer a broad range of microbial control solutions, which help to create and maintain a healthy environment.

Founded in 1897 in the Swiss Alps, Lonza today operates in 120 sites and offices in more than 35 countries. With approximately 15,500 full-time employees, we are built from high-performing teams and of individual employees who make a meaningful difference to our own business, as well as the communities in which we operate. The company generated sales of CHF 5.9 billion in 2019 with a CORE EBITDA of CHF 1.6 billion.

About FUJIFILM

FUJIFILM Cellular Dynamics, Inc. (FCDI) is a leading developer and manufacturer of human induced pluripotent stem cells (iPSCs) utilized in drug discovery and cell therapies. FCDI is using its expertise in iPSC technologies to develop a robust cell therapeutics pipeline to address unmet medical needs in areas such as age-related macular degeneration, retinitis pigmentosa and immuno-oncology. For its partners, FCDI utilizes its iPSC platform to advance the progress of therapeutic candidates in the clinic and provides contract development and manufacturing (CDMO) services. In addition to cell therapy, FCDI also offers life science research tools including the company's inventoried iCell products, which are available in almost any cell type and are sourced from multiple cell lines which can be applied for target identification as well as toxicity testing. The company also offers custom cell development services and cell banking. FCDI's goal is to leverage the vast utility of iPSCs to advance human health and improve the quality of life for patients around the world.

FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, highly functional materials, document and imaging products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2020, the company had global revenues of $21 billion, at an exchange rate of 109 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship.

Contact:

Dr. Sanna Fowler

Tel: +41 61 316 8929

Email: sanna.fowler@lonza.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ('SGX-ST'). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual. Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release. All product and company names herein may be trademarks of their registered owners.

(C) 2020 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
FUJIFILM HOLDINGS CORPORATION -0.62% 6094 End-of-day quote.12.06%
LONZA GROUP AG -0.78% 582.8 Delayed Quote.2.46%
All news about FUJIFILM HOLDINGS CORPORATION
01/06FUJIFILM : says will invest $2 billion in new large-scale cell culture productio..
RE
2020DR REDDY LABORATORIES : . Reddy's Lab's Canadian Unit Seeks Health Canada's Appr..
MT
2020APPILI THERAPEUTICS : Appli Therapeutics Up 3% As Consortium Files Application f..
MT
2020DR REDDY LABORATORIES : . Reddy's Files Application in Canada for COVID-19 Treat..
MT
2020Nikkei hits 3-week low as new virus strain damps recovery hopes
RE
2020Japanese shares drop as new virus strain sparks profit-taking
RE
2020CORRECTION ( : Vietnam-Fujifilm:)
AQ
2020FUJIFILM : Japan's Fujifilm to make coronavirus antigen testing kits in Vietnam
AQ
2020Japan review of Avigan says efficacy for COVID-19 treatment inconclusive -Kyo..
RE
2020SYNTHETICMR : product to be available in Fujifilm's Synapse PACS solution to cus..
AQ
More news
Financials
Sales 2021 2 185 B 21 002 M 21 002 M
Net income 2021 132 B 1 268 M 1 268 M
Net Debt 2021 202 B 1 943 M 1 943 M
P/E ratio 2021 18,4x
Yield 2021 1,57%
Capitalization 2 436 B 23 497 M 23 421 M
EV / Sales 2021 1,21x
EV / Sales 2022 1,12x
Nbr of Employees 73 906
Free-Float 73,9%
Chart FUJIFILM HOLDINGS CORPORATION
Duration : Period :
FUJIFILM Holdings Corporation Technical Analysis Chart | 4901 | JP3814000000 | MarketScreener
Technical analysis trends FUJIFILM HOLDINGS CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Average target price 6 793,33 JPY
Last Close Price 6 094,00 JPY
Spread / Highest target 64,1%
Spread / Average Target 11,5%
Spread / Lowest Target -13,0%
EPS Revisions
Managers and Directors
NameTitle
Shigetaka Komori Chairman & Group Chief Executive Officer
Kenji Sukeno President, Group COO & Representative Director
Takashi Iwasaki Director & Chief Technology Officer
Kouichi Tamai Director & Vice President
Takatoshi Ishikawa Director
Sector and Competitors
1st jan.Capitalization (M$)
FUJIFILM HOLDINGS CORPORATION12.06%23 497
CANON INC.10.31%22 654
BROTHER INDUSTRIES, LTD.9.74%6 001
RICOH COMPANY, LTD.8.42%5 360
TOSHIBA TEC CORPORATION2.68%2 038
KONICA MINOLTA, INC.4.06%2 034